US HB4158 | 2019-2020 | 116th Congress
Status
Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on August 2 2019 - 25% progression, died in committee
Action: 2019-08-05 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on August 2 2019 - 25% progression, died in committee
Action: 2019-08-05 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Prohibits price gouging by manufacturers of prescription drugs (including a combination of a drug, device, or biological product) that are covered by a federal health care program. The bill specifies percentage increases in price at which price gouging is presumed.
Title
CURE High Drug Prices Act Combatting Unreasonable Rises and Excessively High Drug Prices Act
Sponsors
Rep. Chellie Pingree [D-ME] |
History
Date | Chamber | Action |
---|---|---|
2019-08-05 | House | Referred to the Subcommittee on Health. |
2019-08-02 | House | Referred to the House Committee on Energy and Commerce. |
2019-08-02 | House | Introduced in House |
Same As/Similar To
SB637 (Same As) 2019-02-28 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Subjects
Administrative remedies
Civil actions and liability
Health
Health care costs and insurance
Health care coverage and access
Health programs administration and funding
Inflation and prices
Prescription drugs
Civil actions and liability
Health
Health care costs and insurance
Health care coverage and access
Health programs administration and funding
Inflation and prices
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/116th-congress/house-bill/4158/all-info |
Text | https://www.congress.gov/116/bills/hr4158/BILLS-116hr4158ih.pdf |